Month: September 2017

This webinar introduces you to the Patented Medicine Prices Review Board (PMPRB), how they regulate drug pricing in Canada and the proposed changes that will affect cancer patients. This webinar also provides you with the following information: Summary, analysis and next steps regarding proposed price regulation changes Patient perspectives on the proposed reforms Discussion on potential impact, issues and opportunities from these proposed changes How patients

KIRKLAND, QC, Sept. 20, 2017 /CNW Telbec/ – Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that KEYTRUDA® (pembrolizumab) as monotherapy is now indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have high PD-L1 expression, with no EGFR or ALK genomic tumour aberrations and no prior systemic chemotherapy treatment. A validated biomarker test to determine a patient’s tumour proportion score

This marks an important first step towards providing Canadian women with access to this treatment MISSISSAUGA, ON, Sept. 21, 2017 /CNW/ – AstraZeneca Canada is pleased to announce that the pan-Canadian Oncology Drug Review (pCODR) has provided an overwhelmingly positive clinical recommendation for the reimbursement of Lynparza® (olaparib), a first-of-its-kind treatment for BRCA-mutated ovarian cancer.1 Lynparza is an oral, potent inhibitor of poly (ADP-ribose) polymerase (PARP) available as a maintenance

“Cancer-associated thrombosis (CAT) is one of the most common yet preventable causes of death among cancer patients. With over 20,000 Canadians being diagnosed with cancer each year, knowing about causes, prevention, and treatment of CAT will be critical to the quality of life and long-term survival of these individuals. CAT refers to blood clots that can occur in people living with cancer. They may be related

On November 15-16, 2017 from 8:30 a.m. – 5:00 p.m., you are invited to join the Save Your Skin Foundation, the Canadian Cancer Survivor Network and the Schizophrenia Society of Ontario and other patient groups for the second annual Drug Pricing Policy Summit – Measuring Progress and Making Our Mark. This year’s Summit will build on the inaugural 2016 Summit with updates from across the

Grade 6 boys in Saskatchewan will now receive a vaccine to prevent some types of cancer. Starting this year 7,500 boys will be eligible to receive the human papillomavirus, or HPV, vaccine. “If you knew you could prevent cancer and your son or daughter develops that cancer, and they still might, but if you had an opportunity to try and prevent that when they were